成長/分化因子8治療薬市場:パイプラインレビュー(2019年下半期)

◆英語タイトル:GrowthDifferentiation Factor 8 - Pipeline Review, H2 2019
◆商品コード:GDATA20MY0426
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2019年12月27日
◆ページ数:81
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,500 ⇒換算¥378,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD7,000 ⇒換算¥756,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD10,500 ⇒換算¥1,134,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

GrowthDifferentiation Factor 8 – Pipeline Review, H2 2019
Summary

According to the recently published report ‘GrowthDifferentiation Factor 8 – Pipeline Review, H2 2019′; Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) pipeline Target constitutes close to 10 molecules.

Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) – Myostatin also known as growth differentiation factor 8 or GDF-8 is a myokine a protein produced and released by myocytes. This protein is part of the transforming growth factor beta (TGFβ) superfamily. Myostatin is found almost in muscles used for movement, where it is active both before and after birth. This protein normally restrains muscle growth, ensuring that muscles do not grow too large.

The report ‘GrowthDifferentiation Factor 8 – Pipeline Review, H2 2019′ outlays comprehensive information on the Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase II, Phase I and Preclinical stages are 1, 4, 2 and 3 respectively. Report covers products from therapy areas Central Nervous System, Genetic Disorders, Musculoskeletal Disorders, Hematological Disorders and Oncology which include indications Amyotrophic Lateral Sclerosis, Spinal Muscular Atrophy (SMA), Duchenne Muscular Dystrophy, Anemia, Charcot-Marie-Tooth Disease, Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva), Limb-Girdle Muscular Dystrophy, Muscle Wasting Disorders, Myelodysplastic Syndrome, Myelofibrosis, Neuro Muscular Disorders, Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), Post-Polycythemia Vera Myelofibrosis (PPV-MF) and Thalassemia.

Scope

- The report provides a snapshot of the global therapeutic landscape for Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN)
- The report reviews Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) targeted therapeutics and enlists all their major and minor projects
- The report assesses Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) – Overview
Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) – Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) – Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) – Companies Involved in Therapeutics Development
Acceleron Pharma Inc
Biogen Inc
Bioleaders Corp
Chugai Pharmaceutical Co Ltd
PeptiDream Inc
Pfizer Inc
Regeneron Pharmaceuticals Inc
Scholar Rock Inc
Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) – Drug Profiles
ALG-802 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BIIB-110 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BLSM-22 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
domagrozumab – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
efmitermant alfa – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
luspatercept – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RG-70240 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SRK-015 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptide to Inhibit Myostatin for Duchenne Muscular Dystrophy – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
trevogrumab – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) – Dormant Products
Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) – Discontinued Products
Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) – Product Development Milestones
Featured News & Press Releases
Dec 09, 2019: Reblozyl (luspatercept-aamt) studies evaluating treatment of Anemia in rare blood diseases presented at American Society of Hematology (ASH) annual meeting
Dec 06, 2019: Bristol-Myers Squibb and Acceleron Pharma provide update on FDA Advisory Committee for Reblozyl (luspatercept-aamt)
Dec 03, 2019: Bristol-Myers Squibb and Acceleron Pharma announce FDA Advisory Committee will review Reblozyl (luspatercept-aamt) for Use in patients with myelodysplastic syndromes
Nov 19, 2019: Scholar Rock reports preliminary pharmacokinetic and pharmacodynamic data from TOPAZ phase 2 trial of SRK-015 for the treatment of patients with spinal muscular atrophy
Nov 11, 2019: Celgene-Acceleron’s Reblozyl gets US approval to treat anaemia
Nov 08, 2019: FDA approves REBLOZYL (luspatercept-aamt) for the treatment of anemia in adults with beta thalassemia who require regular red blood cell transfusions
Nov 06, 2019: Celgene to present abstracts on Luspatercept at American Society of Hematology (ASH) 2019 Annual Meeting
Nov 06, 2019: Acceleron announces Luspatercept presentations at the 61st American Society of Hematology Annual Meeting
Oct 02, 2019: Scholar Rock to Present Preclinical and Phase 1 Clinical Data on SRK-015 at the World Muscle Society Congress
Sep 16, 2019: Acceleron announces topline results from the phase 2 trial of ACE-083 in patients with Facioscapulohumeral Muscular Dystrophy
Sep 05, 2019: Scholar Rock announces appointment of George Nomikos, M.D., Ph.D., as Vice President, Head of Medical Research, Muscle Franchise
Jun 06, 2019: FDA agrees to review Celgene-Acceleron’s luspatercept in anaemia
Jun 03, 2019: Scholar Rock announces positive final results from Phase 1 clinical trial of SRK-015 in healthy volunteers
May 09, 2019: Scholar Rock starts patient dosing in Phase II study of SRK-015 in SMA
May 08, 2019: Scholar Rock announces initiation of patient dosing in Phase 2 trial of SRK-015 in Spinal Muscular Atrophy
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indication, H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Acceleron Pharma Inc, H2 2019
Pipeline by Biogen Inc, H2 2019
Pipeline by Bioleaders Corp, H2 2019
Pipeline by Chugai Pharmaceutical Co Ltd, H2 2019
Pipeline by PeptiDream Inc, H2 2019
Pipeline by Pfizer Inc, H2 2019
Pipeline by Regeneron Pharmaceuticals Inc, H2 2019
Pipeline by Scholar Rock Inc, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Discontinued Products, H2 2019

【掲載企業】

Acceleron Pharma Inc
Biogen Inc
Bioleaders Corp
Chugai Pharmaceutical Co Ltd
PeptiDream Inc
Pfizer Inc
Regeneron Pharmaceuticals Inc
Scholar Rock Inc

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[成長/分化因子8治療薬市場:パイプラインレビュー(2019年下半期)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆